Skip to Content
Merck
All Photos(1)

Documents

SML1606

Sigma-Aldrich

Oseltamivir phosphate

≥98% (HPLC)

Synonym(s):

GS4104, (3R,4R,5S)-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester phosphate salt

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C16H28N2O4 ·H3PO4
CAS Number:
Molecular Weight:
410.40
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -26 to -36°, c = 1 in H2O

color

white to beige

solubility

H2O: 30 mg/mL, clear

storage temp.

−20°C

SMILES string

OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1

InChI

1S/C16H28N2O4.H3O4P/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19;1-5(2,3)4/h9,12-15H,5-8,17H2,1-4H3,(H,18,19);(H3,1,2,3,4)/t13-,14+,15+;/m0./s1

InChI key

PGZUMBJQJWIWGJ-ONAKXNSWSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

Oseltamivir phosphate is an influenza viral neuraminidase inhibitor. Oseltamivir phosphate, an antiviral, is used clinically to treat influenza A and influenza B, and to prevent flu after exposure. Oseltamivir phosphate is hydrolyzed in the liver to its active form, oseltamivir carboxylate, which is an inhibitor of influenza viral neuraminidases essential for viral replication. Oseltamivir has a broad spectrum of activity against a range of influenza A and B subtypes with IC50 values for neuraminidases measured from less than 1 nM to approximately 30 nM, depending on the virus subtype.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Hazard Classifications

Aquatic Chronic 3 - Eye Irrit. 2 - Skin Sens. 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mohamed A Kamal et al.
Antimicrobial agents and chemotherapy, 59(9), 5388-5395 (2015-06-24)
A population drug-disease model was developed to describe the time course of influenza virus with and without oseltamivir treatment and to investigate opportunities for antiviral combination therapy. Data included viral titers from 208 subjects, across 4 studies, receiving placebo and
Brian E Davies
The Journal of antimicrobial chemotherapy, 65 Suppl 2, ii5-ii10 (2010-03-20)
Influenza is a transmissible viral pathogen that continues to cause substantial morbidity and mortality. Oseltamivir is an orally administered antiviral medication that selectively inhibits the influenza neuraminidase enzymes that are essential for viral replication. Treatment of infected children > or
R H Beigi et al.
Clinical pharmacology and therapeutics, 98(4), 403-405 (2015-06-26)
Pregnancy heightens the risk of adverse outcomes from influenza infections. This is true for both seasonal epidemics as well as occasional pandemics. Seasonal influenza vaccines are the focus of disease prevention and are recommended for all pregnant women in any
Shivraj Hariram Nile et al.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 135, 110985-110985 (2019-11-26)
Investigation of antiviral and cytotoxic effect of quercetin 3-glucoside (Q3G) from Dianthus superbus L over influenza virus infection and replication were studied. Moreover, anti-influenza mechanism was screened by time-dependent antiviral assay, virus-induced symptoms and related gene expressions. The blockade of
C Joaquín Cáceres et al.
Emerging microbes & infections, 10(1), 1832-1848 (2021-08-25)
Seasonal influenza A virus (IAV) infections are among the most important global health problems. FDA-approved antiviral therapies against IAV include neuraminidase inhibitors, M2 inhibitors, and polymerase inhibitor baloxavir. Resistance against adamantanes (amantadine and rimantadine) is widespread as virtually all IAV

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service